Given the role of FGFR3 in various diseases, it is a target for therapeutic interventions. In cancer, FGFR3 inhibitors are being developed and tested in clinical trials. These inhibitors aim to block the abnormal signaling pathways activated by mutated FGFR3, thereby inhibiting tumor growth. In skeletal dysplasias, research is ongoing to develop treatments that can modulate FGFR3 activity and correct the underlying growth defects.
